Essentials: Psychedelics for Treating Mental Disorders

This Huberman Lab Essentials episode distills a conversation between neuroscientist Andrew Huberman and Dr. Matthew Johnson, a psychedelics researcher at Johns Hopkins, into a survey of what qualifies a compound as psychedelic, how these substances appear to work in the clinic, and where the real risks lie. Johnson has run controlled psilocybin trials for smoking cessation and cancer-related depression and anxiety, and is now planning studies with psilocybin for PTSD and retired contact-sport athletes. Throughout, he separates what the data supports from what remains speculation.

What counts as a psychedelic

Johnson calls "psychedelic" more of a cultural label than a precise pharmacological one, since it spans several drug classes. The classic psychedelics, including LSD, psilocybin (found in over 200 mushroom species), DMT, and mescaline, act on the serotonin 2A receptor. A second cluster, the NMDA antagonists, includes ketamine and PCP. MDMA stands apart, driving large increases in both dopamine and serotonin, and is sometimes called an entactogen for its capacity to put people in touch with their emotions. What unites the category, Johnson says, is the ability to profoundly loosen the predictive models the brain uses to navigate the world, including the model of a separate, bounded self; he cites rare, credible reports of people believing they could fly, though he stresses such cases are atypical. Why the serotonin 2A receptor produces such dramatic effects is still not well understood.

Inside a psilocybin clinical trial

A volunteer at Johnson's lab undergoes psychiatric screening to rule out disorders such as schizophrenia and bipolar mania, plus cardiovascular screening, then preparation sessions to build trust with the guides present. Participants receive pure, measured psilocybin, typically 20 to 30 mg, not mushrooms. Sessions stay largely free of tasks, since brain imaging or cognitive testing tends to produce a less meaningful experience. Heart rate and blood pressure rise modestly for most; rarely, when they climb too high, a physician gives sublingual nitroglycerin without ending the session.

Letting go, and why change sometimes sticks

Therapeutic value seems tied to surrendering into a narrow, intense experience rather than resisting it. Johnson describes participants who fixate on one percept, a sound, an emotion, even their own heartbeat, and are encouraged to let it expand. One reportedly told him, "Matt, tell me again I can't die, like I feel like my heart is going to rip through my chest." He links this to what people call a bad trip, a sense that reality and one's sense of self are shattering, and suggests, speculatively, that surrendering to it may be the gateway to the mystical or unity-type experience his data associates with better long-term outcomes. His working hypothesis is that lasting change comes from a persisting shift in self-representation, the internal model of "who I am." A smoking-cessation participant, after repeated failed quit attempts, described a session realization: "My god, it's like I can really just decide." Johnson calls these "duh experiences," where people arrive at conclusions they had heard before but now feel as agency. He connects this to plans to study psilocybin for PTSD alongside the more established MDMA-assisted approach; MDMA, he notes, may suit trauma work for more people partly because severe bad trips are less common with it than with classic psychedelics.

The real dangers

Johnson names two main risks: people with untreated psychotic disorders such as schizophrenia or bipolar mania, screened out of his trials, and the far more common bad trip. Even in a controlled setting, at a roughly 30 mg psilocybin dose after careful preparation, about a third of participants report a period of strong anxiety, fear, or a sense of losing their mind at some point, sometimes followed minutes later by one of the best experiences of their life. See Psylopedia's safety and harm reduction guide for more.

Two frontiers with thin evidence: microdosing and brain injury

Johnson is openly skeptical of microdosing. Credible peer-reviewed studies have not shown benefits for the two main claims in circulation, a stimulant-like boost or a mood lift comparable to a low-dose antidepressant; the limited data that exists shows no effect or mild impairment, including reduced accuracy on time-estimation tasks. He distinguishes this from cyclical dosing protocols promoted by advocates, which have not been tested in controlled research; his own anecdote-based guess favors a possible modest antidepressant effect over any boost to creativity. Psylopedia's microdosing research overview covers this evidence gap. The episode closes on Johnson's most exploratory work: whether psilocybin could help repair damage from repetitive head impacts, drawing on retired-athlete anecdotes and rodent neuroplasticity research. He is planning a study with retired MMA athletes, aiming first at depression and, secondarily, at cognitive gains and brain changes on MRI. He flags this as very early: anecdotes and rodent data exist, but clinical proof does not.

Key takeaways

• ●"Psychedelic" spans several drug classes: serotonin 2A agonists like LSD and psilocybin, NMDA antagonists like ketamine, and MDMA, an entactogen that stands apart.
• ●The shared mechanism, in Johnson's framing, is a loosening of the brain's predictive models, up to the sense of a separate self.
• ●Hopkins trials use pure, measured psilocybin doses (roughly 20 to 30 mg) in a screened, guide-supported setting, not recreational mushroom use.
• ●Letting go of control during a difficult moment may be linked to the transcendental-type experiences tied to better outcomes, a link Johnson calls speculative.
• ●A persisting shift in self-representation may be the common thread behind lasting change after psilocybin or MDMA-assisted therapy.
• ●About a third of participants in Johnson's high-dose psilocybin studies report a bad-trip episode at some point, even under ideal, well-prepared conditions.
• ●Peer-reviewed evidence does not support the specific benefits claimed for microdosing; Johnson's own guess favors a possible mild antidepressant effect over cognitive enhancement.
• ●Using psilocybin for brain injury from repetitive head impact is an early, exploratory direction, not an established treatment.